SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-046860
Filing Date
2022-04-18
Accepted
2022-04-18 16:11:07
Documents
4
Period of Report
2022-06-02

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm223565d1_def14a.htm DEF 14A 260394
2 GRAPHIC tm223565d1_def14asp1img001.jpg GRAPHIC 5762
3 GRAPHIC tm223565d1_def14aimg002.jpg GRAPHIC 133151
4 GRAPHIC tm223565d1_def14aimg003.jpg GRAPHIC 508033
  Complete submission text file 0001104659-22-046860.txt   1153013
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39202 | Film No.: 22832265
SIC: 2834 Pharmaceutical Preparations